Among OCa subtypes, KRAS mutations are frequently observed in borderline serous tumors, low-grade serous ovarian cancer (LGSOC), and mucinous ovarian cancer (MOC), with reported mutation frequencies ranging around 33–41%, 35–54%, and 57.1%, respectively. This evidence concerns the gene KRAS and oculocutaneous albinism.